Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 12 of the 13 calendar months from Oct 2025 to Oct 2026: Nov 2025, Dec 2025, Jan 2026, Feb 2026, Mar 2026, Apr 2026, May 2026, Jun 2026, Jul 2026, Aug 2026, Sep 2026 and Oct 2026.
- Largest single sale: $890K (10,176 shares) of Spyre Therapeutics, Inc. on Jul 1, 2026. Filing
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Chief Executive Officer, Director | Jun 30, 2023 | Oct 2, 2026 |
| Oruka Therapeutics, Inc. (ORKA) | Director | Sep 6, 2024 | Jun 3, 2025 |
| BridgeBio Pharma, Inc. (BBIO) | Former Senior Vice President, Portfolio Management and Corporate Development | Jun 27, 2019 | Dec 29, 2020 |
Also a director at
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Oct 1, 2026, Spyre Therapeutics, Inc.: sold 15,000 shares for $1.4M, under a disclosed plan. 1 filing: 1
- Sep 1, 2026, Spyre Therapeutics, Inc.: sold 15,000 shares for $1.3M, under a disclosed plan. 1 filing: 1
- Aug 3, 2026, Spyre Therapeutics, Inc.: sold 15,000 shares for $1.4M, under a disclosed plan. 1 filing: 1
- Jul 1, 2026, Spyre Therapeutics, Inc.: sold 15,000 shares for $1.3M, under a disclosed plan. 1 filing: 1
- Jun 1, 2026, Spyre Therapeutics, Inc.: sold 15,000 shares for $1.1M, under a disclosed plan. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.